Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Serotonin reuptake inhibitor withdrawal

N J Coupland1, C J Bell, J P Potokar

  • 1Department of Psychiatry, University of Alberta, Edmonton, Canada.

Journal of Clinical Psychopharmacology
|October 1, 1996
PubMed
Summary

Discontinuation symptoms from serotonin reuptake inhibitors (SRIs) like fluvoxamine and paroxetine are more common than from longer-acting SSRIs. These withdrawal effects, including dizziness and nausea, often occur even with slow tapering.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of transient noise in Advanced LIGO relevant to gravitational wave signal GW150914.

Classical and quantum gravity·2020
Same author

GW150914: First results from the search for binary black hole coalescence with Advanced LIGO.

Physical review. D. (2016)·2020
Same author

Prospects for Observing and Localizing Gravitational-Wave Transients with Advanced LIGO and Advanced Virgo.

Living reviews in relativity·2017
Same author

The response to sulpiride in major depression before and after cognitive behavioural therapy: D2 receptor function.

Acta neuropsychiatrica·2016
Same author

Properties of the Binary Black Hole Merger GW150914.

Physical review letters·2016
Same author

Don't panic. A guide to tryptophan depletion with disorder-specific anxiety provocation.

Journal of psychopharmacology (Oxford, England)·2016

Area of Science:

  • Psychopharmacology
  • Neuroscience
  • Clinical Psychiatry

Background:

  • Serotonin reuptake inhibitors (SRIs) are widely prescribed for various psychiatric conditions.
  • Abrupt cessation or rapid tapering of SRIs can lead to discontinuation symptoms.
  • Understanding the differential risk of withdrawal symptoms across different SRIs is crucial for patient management.

Purpose of the Study:

  • To investigate the incidence and characteristics of withdrawal symptoms associated with clomipramine and various selective serotonin reuptake inhibitors (SSRIs).
  • To compare the frequency of discontinuation symptoms between short half-life SSRIs (fluvoxamine, paroxetine) and long half-life SSRIs (sertraline, fluoxetine), as well as clomipramine.

Main Methods:

  • Retrospective chart review of 352 patients treated with clomipramine or SSRIs (fluoxetine, fluvoxamine, paroxetine, sertraline).

Related Experiment Videos

  • Analysis focused on 171 patients with supervised medication tapering and discontinuation.
  • Defined 'cases' as patients experiencing at least one qualitatively new symptom during withdrawal.

    • Main Results:

    • Common withdrawal symptoms included dizziness, lethargy, paresthesia, nausea, vivid dreams, irritability, and lowered mood.
    • Significantly higher incidence of new symptoms in patients treated with short half-life SSRIs (fluvoxamine, paroxetine) or clomipramine (17.2% and 30.8%) compared to long half-life SSRIs (sertraline, fluoxetine) (1.5%).
    • Discontinuation symptoms occurred despite slow tapering, persisted for up to 21 days, and were relieved by re-initiating medication.

    Conclusions:

    • Short half-life SSRIs (fluvoxamine, paroxetine) and clomipramine are associated with a higher risk of discontinuation symptoms compared to long half-life SSRIs.
    • The pathophysiology may involve serotonin's role in coordinating sensory, autonomic, and motor functions.
    • These findings highlight the importance of considering medication half-life during SRI tapering to minimize withdrawal effects.